Clik here to view.
MSKCC unveils large-scale genomic analysis of prostate cancer
Earlier today, an interdepartmental research team from Memorial Sloan-Kettering Cancer Center in New York published the most comprehensive genomic prostate cancer database available to date. Taylor et...
View ArticleClik here to view.
Oncotype DX prostate cancer test: ready for prime time?
A media release issued yesterday by Genomic Health, Inc. states that its Oncotype DX prostate cancer test has shown positive results in a prospective clinical validation study. Specifically, the...
View ArticleClik here to view.
Another potential genomic test for prostate cancer aggression
In a presentation given last Saturday at the annual meeting of the European Society for Radiotherapy and Oncology (ESTRO) in Vienna, a Canadian research team introduced yet another potential test that...
View ArticleClik here to view.
When test “validation” raises questions about levels of validity
There is something of a fuss emerging about data presented at the American Urological Association annual meeting and a claim that these data imply that Myriad Genetics’ genomic Prolaris test ‘has been...
View ArticleClik here to view.
Genomic/genetic tests for risk for clinically significant prostate cancer
The precise ability of the various genetic/genomic tests now available to accurately analyze the risk for clinically significant prostate cancer based on biopsy tissue samples is an important factor...
View ArticleClik here to view.
Medicare may soon cover Prolaris, Decipher tests for prostate cancer
Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of...
View ArticleClik here to view.
Genomic classifier can help identify patients who may not need adjuvant...
A decision that tortures patients with adverse findings (positive margins, and/or stage T3/4) after prostatectomy is whether to jump into adjuvant radiation right away, or wait until PSA rises to 0.2...
View ArticleClik here to view.
How many “different” types of prostate cancer are there?
This, of course, is a rhetorical question. We really have no good idea how many “different” types of prostate cancer there are. And so what we are really dealing with here is how we are going to...
View ArticleClik here to view.
Prolaris test data change clinician, patient decisions about prostate cancer...
A new paper in the Journal of Urology provides us with some interesting if preliminary information on the ways that genetic/genomic tests of biopsy samples may be affecting first-line treatments for...
View ArticleClik here to view.
Salvage radiation therapy and the need for concurrent ADT; the value of the...
A paper given at the recent annual meeting of the American Society for Radiation Ocology (ASTRO) suggests that the Decipher genomic classifier may help to distinguish between treatment options for men...
View ArticleClik here to view.
Upcoming prostate cancer CureTalk on February 9
The next, scheduled prostate cancer CureTalk will be at 6:00 p.m. Eastern time on February 9, 2016, and will address the use of newer imaging and genomic testing methods in the diagnosis and management...
View ArticleClik here to view.
CureTalk program on imaging and genomics with Dr. David Lee
Yesterday evening we held a CureTalk program on the roles of new imaging and genomic/genetic tests in the diagnosis, work-up, and prognosis of prostate cancer with Dr. David Lee of the University of...
View ArticleClik here to view.
Are you a good candidate for the TAPUR study? If so, sign up!
Nearly a year ago now, the American Society of Clinical Oncology (ASCO) first announced plans to initiate an innovative trial of a personalized medicine initiative called the Targeted Agent and...
View ArticleClik here to view.
Individualizing precision therapy for advanced prostate cancer
There’s a very interesting article this week on the Hutch News pages of the Fred Hutchinson Cancer Research Center (in Seattle, WA). It addresses the degree to which metastatic prostate cancer may be...
View ArticleClik here to view.
Just how accurate are current genetic/genomic tests in the diagnosis and...
As we have pointed out regularly over the years, all prostate cancers are by no means the same. And a recently published paper in European Urology makes the inherent diversity in the subtypes of...
View ArticleClik here to view.
The cost and the effectiveness of genomic testing for prostate cancer risk
As regular readers will be well aware, there are now several different tests available that can be used to assess risk for low- and very low-risk forms of prostate cancer at time of diagnosis (as...
View ArticleClik here to view.
Genomic prediction of risk for biochemical relapse post-surgery
Yet another genetic/genomic test (this one developed by Metamark Genetics) may have value in the assessment of risk for biochemical progression after first-line surgery for prostate cancer. According...
View ArticleClik here to view.
Genetics, genomics, targeted therapy, and the costs of care
A new paper in a new journal argues that all men diagnosed with advanced forms of prostate cancer should now, routinely, be undergoing tumor and germline DNA profiling so as to guide enrollment into...
View ArticleClik here to view.
Can the Decipher test accurately project risk for metastasis post-surgery?
A newly published article in the Journal of Clinical Oncology suggests that the Decipher test may be able to predict risk for metastatic prostate at 10 years post-surgery. However, there are serious...
View ArticleClik here to view.
Some “Best of ASCO” reports from UroToday
The UroToday web site has now posted a number of “Best of ASCO” reports that might be of interest to some of our readers. We have already reported on some of these issues, but it’s never a bad idea to...
View Article